CMS Creates Regulatory Pathway For Altering Protected Classes Under Part D
This article was originally published in The Pink Sheet Daily
Executive Summary
Potential changes to current list of six protected classes will be reviewed by “expert panel” and subject to public rulemaking process.
You may also be interested in...
CMS Revisits Part D "Protected Classes" Rule
CMS drops proposal for a panel of outside experts, but still wants a "data-driven" process for selecting protected drug classes.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.